~30 percent of seniors have sequelae after acute SARS-CoV-2
Feb 10, 2022
The greatest excess risk was seen for respiratory failure, fatigue, hypertension and memory difficulties compared with matched individuals without COVID-19.
Telehealth may not be as thrifty as many think, researchers find
By
Aaron Dorman
Jul 13, 2023
While expanding virtual health options offers a number of benefits to patients and providers, the assumption that telehealth will universally lower costs may be overstated, experts caution.
Associations join forces in call for Provider Relief Fund changes
By
Kimberly Bonvissuto
Mar 03, 2022
Long-term care industry advocates joined forces Tuesday in support of a bill delaying paperwork requirements and expanding the uses for Provider Relief Fund dollars. They also urged leaders in Congress...
Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
Fourth mRNA COVID-19 vaccine immunogenic, safe
Mar 24, 2022
Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Flu vaccine may protect against adverse events after SARS-CoV-2
Aug 17, 2021
Individuals who had received a flu vaccination had lower risks for sepsis, stroke and deep vein thromboses as well as emergency department and ICU admissions
New COVID-19 cases 300 percent higher this Labor Day weekend than last year
Sep 07, 2021
The surge in new cases could really hit a high point in about two weeks from now.
Social isolation contributes to increased likelihood of dementia: study
By
Kimberly Bonvissuto
Jan 11, 2023
Social isolation is common among older adults in the United States — experienced by one in four of them — and increases the likelihood of developing dementia, according to the results of a new study.
Temporal improvement seen in standard of care for hospitalized COVID-19 patients
Nov 30, 2022
Outcomes improved from the Adaptive COVID-19 Treatment Trial-2 to ACTT-3, although potential explanatory factors were similar.
Studies compare various treatments for COVID-19
Nov 28, 2022
Sotrovimab was effective compared with molnupiravir; a second study shows no effect for angiotensin receptor blockers in terms of illness severity.